¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"labile phosphate group"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • haptenic group
    ºÒ¿ÏÀüÇ׿ø±º, ÇÕÅÙ±º
  • linkage group
    ¿¬°ü±º
  • low risk group
    ÀúÀ§Ç豺
  • methyl group
    ¸ÞÆ¿±â
  • osmophore group
    ¹ßÇâ´Ü(Û¡úÅÓ¥)
  • prosthetic group
    1. º¸°áºÐÀÚ´Ü 2. º¸°á¿øÀÚ´Ü
  • Rh blood group system
    RhÇ÷¾×Çüü°è
  • soluble group
    °¡¿ëÇØ±º
  • self-help group
    ÀÚ°¡µµ¿òÁý´Ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • green or yellow vegetable group
    ³ìȲ»öä¼Ò·ù
  • group hospital
    º´¿øÁ¶ÇÕ
  • group medicine
    Áý´ÜÁø·á, Çùµ¿Áø·á
  • group practice
    Áý´Ü°³¾÷
  • group psychotherapy
    Áý´ÜÁ¤½Å¿ä¹ý
  • group displacement law
    Áý´Üº¯À§¹ýÄ¢
  • group fascicular repair
    ½Å°æ¼¶À¯´Ù¹ß±ººÀÇÕ(¹ý)
  • group reference value
    Áý´Ü±âÁØÄ¡
  • haptenic group
    ºÒ¿ÏÀüÇ׿ø±º, ÇÕÅÙ±º
  • high risk group
    °íÀ§Çèµµ±º
  • index group
    ÃʹßȯÀÚ±º
  • linkage group
    ¿¬°ü±º
  • marathon group
    ¸¶¶óÅæÁý´Ü
  • methyl group
    ¸ÞÆ¿±â
  • minority group
    ¼Ò¼öÁý´Ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Rh blood group
    Rh Ç÷¾×Çü
  • Rh blood group system
    Rh Ç÷¾×Çü±º
  • amino group
    ¾Æ¹Ì³ë±â(¡­Ðñ).
  • analytic group psychotherapy
    ºÐ¼®Àû Áý´Ü Á¤½ÅÄ¡·á
  • anterior sinus group
    ÀüºÎºñµ¿±º
  • functional group
    ÀÛ¿ë±â(íÂéÄÐñ).
  • green or yellow vegetable group
    ³ìȲ»öä¼Ò·ù.
  • group
    ±º
  • group I fiber
    Á¦¥°¤Çí·A(ð¯ìéÏØàéë«).
  • group I fiber
    Á¦¥°±º¼¶À¯(ð¯ìéÏØàéë«).
  • group II fiber
    Á¦¥±¤Çí·A.
  • group II fiber
    Á¦¥± ±º¼¶À¯(ÏØàéë«).
  • group III fiber
    Á¦¥²¤Çí·A.
  • group III fiber
    Á¦¥²±º¼¶À¯(ÏØàéë«).
  • group IV fiber
    Á¦¥³¤Çí·A.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • magnesium ammonium phosphate
    ¾Ï¸ð´½Àλ긶±×³×½·
  • magnesium ammonium phosphate stones
    ¸¶±×³×½· ¾Ï¹¦´½ Àλ꿰¼®(¡­ ×òß«ç¤à´)
  • magnesium phosphate crystal
    Àλ긶±×³×½·°áÁ¤
  • pentose phosphate pathway
    ¿Àź´ç ÀλêÈ­ ¹ÝÀÀ
  • phosphate
    Àλ꿰
  • phosphate
    Àλ꿰(ìÝß«ç¤).
  • phosphate buffer
    Àλ꿰¿ÏÃæ¾×
  • phosphate dehydrogenase deficiency
    Àλ꿰ݼö¼ÒÈ¿¼Ò°áÇÌÁõ
  • phosphate diabetes
    Àλ꿰´ç´¢
  • phosphate reabsorption
    Àλ꿰ÀçÈí¼ö
  • potassium dihydrogen phosphate
    ÀλêÀ̼ö¼Ò(ì£â©áÈ)Ä®·ý
  • pyridoxal phosphate
    ÀλêÇǸ®µ¶»ì.
  • saline, phosphate-buffered (PBS)
    Àλ꿰¿ÏÃæ½Ä¿°¼ö, PBS
  • stellar phosphate
    ¼º»óÀλ꿰(àøßÒìÝß«ç¤).
  • tricresyl phosphate
    Àλê(ìÝß«)Æ®¸®Å©·¹½Ç.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • azo group
    ¾ÆÁ¶±â(Ðñ)
  • bathochromic group
    ÀåÆÄ»ö´Ü±º(íþ÷îßäÓ¥ÏØ)
  • blocking group
    Â÷´Ü±â(ó´Ó¨Ðñ)
  • carbamoyl group
    Ä«¸£¹Ù¸ðÀÏ ±â(Ðñ)
  • carbonyl group
    Ä«¸£º¸´Ò±â(Ðñ)
  • carboxyl group
    Ä«¸£º¹½Ç±â(Ðñ)
  • complementation group
    »óº¸±º(ßÓÜÍÏØ)
  • critical group
    ÀӰ豺(×üÍ£ÏØ)
  • diazo group
    µð¾ÆÁ¶ ±â(Ðñ)
  • diazonium group
    µð¾ÆÁ¶´½ ±â(Ðñ)
  • earthy group
    Å伺±â(÷ÏàõÐñ)
  • end-group analysis
    Á¾´Ü±â ºÐ¼® (ðûÓ®ÐñÝÂà°)
  • fatty acyl group
    Áö¹æ(ò·Û¸) ¾Æ½Ç±â(Ðñ)
  • fidelity group
    Á¤È®µµ ±â(ïáü¬ÓøÐñ)
  • formimino group
    Æ÷¸§À̹̳ë±â(Ðñ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
GPD glucose-6-phosphate dehydrogenase; glycerol-phosphate dehydrogenase
PD Doctor of Pharmacy; Dublin Pharmacopoeia; interpupillary distance; Paget disease; pancreatic duct; p...
PPP pain perception profile; palatopharyngoplasty; palmoplantar pustulosis; pentose phosphate pathway; p...
TCP T-complex protein; therapeutic continuous penicillin; total circulating protein; transcutaneous pace...
CREG Cross REactive Group (of HLA Antigens)
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
group B group A
Group D group
Group I group
group II group I
Group III group
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Rh blood group
    Rh Ç÷¾×Çü, ¾Æ¸£ ¿¡ÀÌÄ¡½Ä Ç÷¾×Çü
    1940³â ¹Ì±¹ÀÇ K. ¶õÆ®½´Å¸ÀÌ³Ê µî¿¡ ÀÇÇÏ¿© ¹ß°ßµÈ ÀÓ»óÀûÀ¸·Î ¾ÆÁÖ Áß¿äÇÑ Ç÷¾×Çü. Rh¶ó´Â °ÍÀº, óÀ½¿¡ À̰ÍÀ» °ËÃâÇϴµ¥ ÇÊ¿äÇÑ Ç×Ç÷ûÀ» ¾ò±â À§ÇÏ¿© »ç¿ëÇÑ ¸é¿ª µ¿¹°ÀÎ ºÓÀºÅпø¼þÀÌ
  • S-blood group
    ¿¡½º½Ä Ç÷¾×Çü
    ABO½Ä Ç÷¾×Çü°ú °ü°è ÀÖ´Â Ç÷¾×Çü. Ç÷¾×ÀÇ ºÐºñÇü, ºñºÐºñÇüÀÇ ºÐ·ù¶ó°í Çϸç, 1932³â µ¶ÀÏÀÇ F. ½ÃÇÁ°¡ ¹ß°ßÇÏ¿´´Ù. ABO½Ä Ç÷¾×Çü¿¡ ¼ÓÇÏ´Â Ç׿ø ¹°Áú
  • zymophore group
    È¿¼ÒÀÛ¿ëÁ·
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
group agglutination Agglutination by antibodies specific for minor (group) antigens common to several microorganisms, each of which possesses its own major specific antigen.
Synonym: cross agglutination.
(05 Mar 2000)
group agglutinin An immune agglutinin specific for a group antigen.
Synonym: cross-reacting agglutinin.
(05 Mar 2000)
group antigens Antigen's that are shared by related genera of microorganisms.
(05 Mar 2000)
group A streptococcal necrotizing fasciitis A complication of infection with GAS (group A streptococci) in which the bacteria attacks and destroys muscle tissue. According to the CDC, 5-10% of people with severe GAS infection develop necrotizing fasciitis. Though the infection can be treated with antibiotics, the fatality rate is close to 30%. This complication often develops as a wound infection after surgery or injury.
(05 Mar 2000)
group A streptococci A common bacteria that is the cause of strep throat, scarlet fever, impetigo, cellulitis-erysipelas, rheumatic fever, acute glomerular nephritis, endocarditis, and group A streptococcal necrotizing fasciitis. The prototype is Streptococcus pyogenes.
(05 Mar 2000)
group B streptococci A leading cause of a form of neonatal sepsis that has a 10-20% mortality rate and leaves a large number of survivors with brain damage. Also a leading cause of meningitis.
(05 Mar 2000)
group dynamics A term used to represent the study of underlying features of group behaviour, e.g., motives, attitudes; it is concerned with group change rather than with static characteristics.
(05 Mar 2000)
group homes Housing for groups of patients, children, or others who need or desire emotional or physical support. They are usually established as planned, single housekeeping units in residential dwellings that provide care and supervision for small groups of residents, who, although unrelated, live together as a family.
(12 Dec 1998)
group hospital A private hospital organised and controlled by a group of physicians and restricted to the reception and care of their own patients.
(05 Mar 2000)
group III mycobacteria Mycobacteria that are either colourless or that slowly produce a light yellow pigment when grown in the presence of light. Organisms placed in this group belong to the species Mycobacterium intracellulare.
Synonym: nonchromogens.
(05 Mar 2000)
group II mycobacteria Mycobacteria that produce a yellow pigment even when grown in the dark; when grown in the light, the pigment is orange. These organisms behave as do saprophytes in humans and are nonpathogenic to laboratory animals.
Synonym: scotochromogens.
(05 Mar 2000)
group immunity <immunology> Resistance of a group to a pathogen due to immunity of a large proportion of the group to that pathogen.
(09 Oct 1997)
group I mycobacteria Mycobacteria that produce a bright yellow colour when grown in the presence of light. Organisms placed in this group appear to belong to the species Mycobacterium kansasii.
Synonym: photochromogens.
(05 Mar 2000)
group IV mycobacteria Mycobacteria that grow rapidly and that do not produce pigment. Organisms placed in this group belong to such species as Mycobacterium ulcerans and M. Marinum.
(05 Mar 2000)
group practice Any group of three or more full-time physicians organised in a legally recognised entity for the provision of health care services, sharing space, equipment, personnel and records for both patient care and business management, and who have a predetermined arrangement for the distribution of income.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • tail group
    TAIL UNIT
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á